{4-[5-(3-chloro-phenoxy)-oxazolo[5,4-d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid for use in the prevention or treatment of acute kidney injury

US9782411B2 · kind B2 · utility

Assignee

• Sanofi · FR

Inventors

• Véronique Briand · Paris, FR
• Sabine Gratzer · Gräfelfing, DE
• Thomas Huebschle · Frankfurt am Main, DE
• Philip Janiak · Gif-sur-Yvette, FR
• Dieter Kadereit · Kelkheim, DE
• Ashfaq Parkar · Piscataway, US
• Bruno Poirier · Paris, FR
• Matthias Schaefer · Frankfurt am Main, DE
• Paulus Wohlfart · Frankfurt am Main, DE

Key dates

• Filing date: Oct 15, 2014
• Grant date: Oct 10, 2017
• Expiry date: Oct 15, 2034

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02P20/582
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

{4-[5-(3-chloro-phenoxy)-oxazolo[5,4-d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid or a pharmaceutically acceptable salt thereof for use in the prevention or treatment of AKI (acute kidney injury). Medicament and pharmaceutical composition thereof.